DOCSLIB.ORG

Table S5-Correlation of Cytogenetic Changes with Gene Expression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S5-Correlation of Cytogenetic Changes with Gene Expression Table S5-Correlation of cytogenetic changes with gene expression in MCF10CA1a FeatureNumCytoband GeneName Description logFC Fold change 28 4087 2p21 TACSTD1 Homo sapiens tumor-associated calcium signal transducer 1 (TACSTD1), mRNA-7.04966 [NM_002354]0.007548158 37 38952 20p12.2 JAG1 Homo sapiens jagged 1 (Alagille syndrome) (JAG1), mRNA [NM_000214] -6.44293 0.011494322 67 2569 20q13.33 COL9A3 Homo sapiens collagen, type IX, alpha 3 (COL9A3), mRNA [NM_001853] -6.04499 0.015145263 72 44151 2p23.3 KRTCAP3 Homo sapiens clone DNA129535 MRV222 (UNQ3066) mRNA, complete cds. [AY358993]-6.03013 0.015302019 105 40016 8q12.1 CA8 Homo sapiens carbonic anhydrase VIII (CA8), mRNA [NM_004056] 5.68101 51.30442111 129 34872 20q13.32 SYCP2 Homo sapiens synaptonemal complex protein 2 (SYCP2), mRNA [NM_014258]-5.21222 0.026975242 140 27988 2p11.2 THC2314643 Unknown -4.99538 0.031350145 149 12276 2p23.3 KRTCAP3 Homo sapiens keratinocyte associated protein 3 (KRTCAP3), mRNA [NM_173853]-4.97604 0.031773429 154 24734 2p11.2 THC2343678 Q6E5T4 (Q6E5T4) Claudin 2, partial (5%) [THC2343678] 5.08397 33.91774866 170 24047 20q13.33 TNFRSF6B Homo sapiens tumor necrosis factor receptor superfamily, member 6b, decoy (TNFRSF6B),-5.09816 0.029194423 transcript variant M68C, mRNA [NM_032945] 177 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.88156 [NM_000930]0.033923737 186 31003 20p11.23 OVOL2 Homo sapiens ovo-like 2 (Drosophila) (OVOL2), mRNA [NM_021220] -4.69868 0.038508469 200 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.78576 [NM_000930]0.036252773 209 9317 2p14 ARHGAP25 Homo sapiens Rho GTPase activating protein 25 (ARHGAP25), transcript variant-4.62265 1, mRNA0.040592167 [NM_001007231] 211 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA -4.7152[NM_000930]0.038070134 212 16979 2p13.1 MGC10955 Homo sapiens hypothetical protein MGC10955, mRNA (cDNA clone MGC:10955-4.70762 IMAGE:3632495),0.038270716 complete cds. [BC004960] 226 17873 2p13.3 TGFA Homo sapiens transforming growth factor, alpha (TGFA), mRNA [NM_003236]-4.80546 0.035761153 227 24069 8q13.3 SULF1 Homo sapiens sulfatase 1 (SULF1), mRNA [NM_015170] 4.79472 27.7558046 238 10756 20q13.31 BMP7 Homo sapiens bone morphogenetic protein 7 (osteogenic protein 1) (BMP7), mRNA-4.74443 [NM_001719]0.037306451 241 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.67472 [NM_000930]0.039153439 253 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.70373 [NM_000930]0.038374016 256 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.71094 [NM_000930]0.038182703 257 4244 20q13.33 SLCO4A1 Homo sapiens solute carrier organic anion transporter family, member 4A1 (SLCO4A1),-4.4338 mRNA0.046269366 [NM_016354] 258 10059 20q13.33 PTK6 Homo sapiens PTK6 protein tyrosine kinase 6 (PTK6), mRNA [NM_005975] -4.41726 0.04680276 261 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.66825 [NM_000930]0.039329442 265 37039 20q13.12 SLPI Homo sapiens secretory leukocyte peptidase inhibitor (SLPI), mRNA [NM_003064]-4.39728 0.047455435 268 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.69536 [NM_000930]0.038597278 277 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.64443 [NM_000930]0.039984186 288 39605 8p11.21 PLAT Homo sapiens plasminogen activator, tissue (PLAT), transcript variant 1, mRNA-4.65348 [NM_000930]0.039734012 291 32344 8q12.1 AK055621 Homo sapiens cDNA FLJ31059 fis, clone HSYRA2000832. [AK055621] 4.30573 19.77667175 296 5333 20q13.12 EYA2 Homo sapiens eyes absent homolog 2 (Drosophila) (EYA2), transcript variant 2,-4.29336 mRNA [NM_172113]0.051000101 304 30720 9p22.1 AK024898 Homo sapiens cDNA: FLJ21245 fis, clone COL01184. [AK024898] -4.26394 0.052050697 308 13188 20q13.33 STMN3 Homo sapiens stathmin-like 3 (STMN3), mRNA [NM_015894] -5.19578 0.027284363 311 20510 20q13.12 SLPI Homo sapiens secretory leukocyte peptidase inhibitor (SLPI), mRNA [NM_003064]-4.2296 0.05330455 324 24279 20p12.1 FLRT3 Homo sapiens fibronectin leucine rich transmembrane protein 3 (FLRT3), transcript-4.387 variant0.047794886 2, mRNA [NM_198391] 332 14493 20q13.12 JPH2 Homo sapiens junctophilin 2 (JPH2), transcript variant 1, mRNA [NM_020433] 4.20088 18.39034261 374 11143 2p14 C2orf32 Homo sapiens chromosome 2 open reading frame 32 (C2orf32), mRNA [NM_015463]4.64416 25.00534113 378 7410 2p24.2 VSNL1 Homo sapiens visinin-like 1 (VSNL1), mRNA [NM_003385] -4.52644 0.043391705 392 43642 20p13 SLC4A11 Homo sapiens solute carrier family 4, sodium bicarbonate transporter-like, member-4.0555 11 (SLC4A11),0.060141128 mRNA [NM_032034] 406 28657 20q13.12 PI3 Homo sapiens peptidase inhibitor 3, skin-derived (SKALP) (PI3), mRNA [NM_002638]-4.4964 0.044304471 412 27477 2p23.3 LOC339778 Homo sapiens cDNA FLJ34164 fis, clone FCBBF3014567. [AK091483] -4.7973 0.035964031 416 44593 8p23.1 ENST00000360178sWSS3420 Eric D. Green Homo sapiens STS cDNA clone 7B04E04, sequence-4.77852 tagged site.0.036435302 [G30702] 428 41456 20q11.23 C20orf102 Homo sapiens chromosome 20 open reading frame 102 (C20orf102), mRNA [NM_080607]3.89398 14.86640223 423 15662 8p23.1 C8orf13 Homo sapiens chromosome 8 open reading frame 13 (C8orf13), mRNA [NM_053279]4.68132 25.65771845 452 20927 20q13.32 SYCP2 Homo sapiens synaptonemal complex protein 2 (SYCP2), mRNA [NM_014258]-5.54167 0.021467958 470 21367 2p16.1 ENST00000233161Homo sapiens mRNA for KIAA1912 protein, partial cds. [AB067499] 4.21931 18.62688614 488 28361 20q13.12 WISP2 Homo sapiens WNT1 inducible signaling pathway protein 2 (WISP2), mRNA [NM_003881]3.72058 13.18272872 497 6733 2p11.2 TGOLN2 Homo sapiens trans-golgi network protein 2 (TGOLN2), mRNA [NM_006464] -4.04294 0.060666976 504 44651 8q13.2 C8orf34 Homo sapiens chromosome 8 open reading frame 34 (C8orf34), mRNA [NM_052958]3.72261 13.20133721 514 15821 20q13.13 KCNG1 Homo sapiens potassium voltage-gated channel, subfamily G, member 1 (KCNG1),-3.7499 transcript0.074330534 variant 1, mRNA [NM_002237] 526 19331 2p24.1 BI058698 BI058698 PM1-GN0499-060401-006-h10 GN0499 Homo sapiens cDNA, mRNA-3.66398 sequence0.078891898 [BI058698] 530 12678 20q13.12 SULF2 Homo sapiens sulfatase 2 (SULF2), transcript variant 1, mRNA [NM_018837] -3.92152 0.065994033 544 33261 20q12 MAFB Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)3.74947 (MAFB),13.44940682 mRNA [NM_005461] 550 33475 8q12.3 A_24_P247205Unknown 3.62918 12.37345333 561 12530 8p11.23 TACC1 Homo sapiens transforming, acidic coiled-coil containing protein 1 (TACC1), mRNA3.72957 [NM_006283]13.26515625 615 36804 20q13.12 EYA2 Homo sapiens eyes absent homolog 2 (Drosophila) (EYA2), transcript variant 2,-3.45369 mRNA [NM_172113]0.091271608 632 828 20q13.13 CD521096 CD521096 AGENCOURT_14355292 NIH_MGC_191 Homo sapiens cDNA clone-3.41836 IMAGE:304108150.093534412 5', mRNA sequence [CD521096] 633 3535 20q13.13 B4GALT5 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide-3.41584 5 (B4GALT5),0.093697831 mRNA [NM_004776] 640 23593 9p13.1 CNTNAP3 Homo sapiens contactin associated protein-like 3 (CNTNAP3), mRNA [NM_033655]-3.40789 0.094215736 659 7516 9p24.2 VLDLR Homo sapiens very low density lipoprotein receptor (VLDLR), transcript variant -3.520161, mRNA [NM_003383]0.087162109 666 33255 9p13.3 AQP3 Homo sapiens aquaporin 3 (Gill blood group) (AQP3), mRNA [NM_004925] -3.85854 0.068938626 676 12567 2p23.1 GALNT14 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase3.66894 12.71920927 14 (GalNAc-T14) (GALNT14), mRNA [NM_024572] 702 42931 2p23.3 CGREF1 Homo sapiens cell growth regulator with EF-hand domain 1 (CGREF1), mRNA -3.36409[NM_006569]0.097119723 698 33432 20p13 TRIB3 Homo sapiens tribbles homolog 3 (Drosophila) (TRIB3), mRNA [NM_021158] -3.31312 0.100612116 743 8193 9p13.1 RP11-138L21.1Homo sapiens cDNA FLJ30083 fis, clone BGGI12001097, weakly similar to Homo-3.24132 sapiens0.105746456 contactin associated protein (Caspr) mRNA. [AK054645] 781 40097 9p13.3 AQP3 Homo sapiens aquaporin 3 (Gill blood group) (AQP3), mRNA [NM_004925] -3.31398 0.100552233 797 23893 8q21.11 RDH10 Homo sapiens retinol dehydrogenase 10 (all-trans) (RDH10), mRNA [NM_172037]-3.63066 0.080735154 803 20306 2p13.1 HK2 Homo sapiens hexokinase 2 (HK2), mRNA [NM_000189] -3.47097 0.090185227 839 44377 9p13.1 CNTNAP3 Homo sapiens contactin associated protein-like 3 (CNTNAP3), mRNA [NM_033655]-3.10109 0.116541211 849 6490 2p22.2 CYP1B1 Homo sapiens cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1),3.32189 mRNA [NM_000104]9.999709112 854 42256 8q12.3 BC040678 Homo sapiens cDNA clone IMAGE:4817707. [BC040678] 3.07738 8.440823164 855 5798 2p22.3 LTBP1 Homo sapiens latent transforming growth factor beta binding protein 1 (LTBP1),3.34948 transcript variant10.19280661 1, mRNA [NM_206943] 871 27596 20q11.22 PROCR Homo sapiens protein C receptor, endothelial (EPCR) (PROCR), mRNA [NM_006404]-3.17936 0.110386936 878 21008 8p21.2 DPYSL2 Homo sapiens dihydropyrimidinase-like 2 (DPYSL2), mRNA [NM_001386] 3.22224 9.332324875 886 496 8q12.1 C8orf72 Homo sapiens chromosome 8 open reading frame 72 (C8orf72), mRNA [NM_147189]3.09399 8.538516277 902 27757 2p23.1 XDH Homo sapiens xanthine dehydrogenase (XDH), mRNA [NM_000379] -3.4198 0.093440847
Load more

Recommended publications
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • A Mendelian Randomization Study Zhifa Han1†, Rui Tian1†, Peng Ren1, Wenyang Zhou1, Pingping Wang1, Meng Luo1, Shuilin Jin2* and Qinghua Jiang1*
    Han et al. BMC Medical Genetics 2018, 19(Suppl 1):0 https://doi.org/10.1186/s12881-018-0721-7 RESEARCH Open Access Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study Zhifa Han1†, Rui Tian1†, Peng Ren1, Wenyang Zhou1, Pingping Wang1, Meng Luo1, Shuilin Jin2* and Qinghua Jiang1* From 29th International Conference on Genome Informatics Yunnan, China. 3-5 December 2018 Abstract Background: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the top two common neurodegenerative diseases in elderly. Recent studies found the α-synuclein have a key role in AD. Although many clinical and pathological features between AD and PD are shared, the genetic association between them remains unclear, especially whether α-synuclein in PD genetically alters AD risk. Results: We did not obtain any significant result (OR = 0.918, 95% CI: 0.782–1.076, P = 0.291) in MR analysis between PD and AD risk. In MR between α-synuclein in PD with AD risk, we only extracted rs356182 as the IV through a strict screening process. The result indicated a significant association based on IVW method (OR = 0. 638, 95% CI: 0.485–0.838, P = 1.20E-03). In order to examine the robustness of the IVW method, we used other three complementary analytical methods and also obtained consistent results. Conclusion: The overall PD genetic risk factors did not predict AD risk, but the α-synuclein susceptibility genetic variants in PD reduce the AD risk. We believe that our findings may help to understand the association between them, which may be useful for future genetic studies for both diseases.
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • Entrez Symbols Name Termid Termdesc 117553 Uba3,Ube1c
    Entrez Symbols Name TermID TermDesc 117553 Uba3,Ube1c ubiquitin-like modifier activating enzyme 3 GO:0016881 acid-amino acid ligase activity 299002 G2e3,RGD1310263 G2/M-phase specific E3 ubiquitin ligase GO:0016881 acid-amino acid ligase activity 303614 RGD1310067,Smurf2 SMAD specific E3 ubiquitin protein ligase 2 GO:0016881 acid-amino acid ligase activity 308669 Herc2 hect domain and RLD 2 GO:0016881 acid-amino acid ligase activity 309331 Uhrf2 ubiquitin-like with PHD and ring finger domains 2 GO:0016881 acid-amino acid ligase activity 316395 Hecw2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 GO:0016881 acid-amino acid ligase activity 361866 Hace1 HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1 GO:0016881 acid-amino acid ligase activity 117029 Ccr5,Ckr5,Cmkbr5 chemokine (C-C motif) receptor 5 GO:0003779 actin binding 117538 Waspip,Wip,Wipf1 WAS/WASL interacting protein family, member 1 GO:0003779 actin binding 117557 TM30nm,Tpm3,Tpm5 tropomyosin 3, gamma GO:0003779 actin binding 24779 MGC93554,Slc4a1 solute carrier family 4 (anion exchanger), member 1 GO:0003779 actin binding 24851 Alpha-tm,Tma2,Tmsa,Tpm1 tropomyosin 1, alpha GO:0003779 actin binding 25132 Myo5b,Myr6 myosin Vb GO:0003779 actin binding 25152 Map1a,Mtap1a microtubule-associated protein 1A GO:0003779 actin binding 25230 Add3 adducin 3 (gamma) GO:0003779 actin binding 25386 AQP-2,Aqp2,MGC156502,aquaporin-2aquaporin 2 (collecting duct) GO:0003779 actin binding 25484 MYR5,Myo1e,Myr3 myosin IE GO:0003779 actin binding 25576 14-3-3e1,MGC93547,Ywhah
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence After Radical Prostatectomy
    Int. J. Mol. Sci. 2015, 16, 3856-3869; doi:10.3390/ijms16023856 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy Chinyere Ibeawuchi 1, Hartmut Schmidt 2, Reinhard Voss 3, Ulf Titze 4, Mahmoud Abbas 5, Joerg Neumann 6, Elke Eltze 7, Agnes Marije Hoogland 8, Guido Jenster 9, Burkhard Brandt 10 and Axel Semjonow 1,* 1 Prostate Center, Department of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: [email protected] 2 Center for Laboratory Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: [email protected] 3 Interdisciplinary Center for Clinical Research, University of Muenster, Albert-Schweitzer-Campus 1, Gebaeude D3, Domagkstrasse 3, Muenster D-48149, Germany; E-Mail: [email protected] 4 Pathology, Lippe Hospital Detmold, Röntgenstrasse 18, Detmold D-32756, Germany; E-Mail: [email protected] 5 Institute of Pathology, Mathias-Spital-Rheine, Frankenburg Street 31, Rheine D-48431, Germany; E-Mail: [email protected] 6 Institute of Pathology, Klinikum Osnabrueck, Am Finkenhuegel 1, Osnabrueck D-49076, Germany; E-Mail: [email protected] 7 Institute of Pathology, Saarbrücken-Rastpfuhl, Rheinstrasse 2, Saarbrücken D-66113, Germany; E-Mail: [email protected] 8 Department
    [Show full text]
  • The Chondroitin Sulfate Moiety Mediates Thrombomodulin-Enhanced Adhesion and Migration of Vascular Smooth Muscle Cells
    Pai et al. Journal of Biomedical Science (2018)25:14 https://doi.org/10.1186/s12929-018-0415-7 RESEARCH Open Access The chondroitin sulfate moiety mediates thrombomodulin-enhanced adhesion and migration of vascular smooth muscle cells Vincent Chunpeng Pai1†, I-Chung Lo2†, Yan wun Huang1, I-Ching Tsai1, Hui-Pin Cheng1, Guey-Yueh Shi2,3, Hua-Lin Wu2,3 and Meei Jyh Jiang1,2* Abstract Background: Thrombomodulin (TM), a transmembrane glycoprotein highly expressed in endothelial cells (ECs), is a potent anticoagulant maintaining circulation homeostasis. Under inflammatory states, TM expression is drastically reduced in ECs while vascular smooth muscle cells (VSMCs) show a robust expression of TM. The functional role of TM in VSMCs remains elusive. Methods: We examined the role of TM in VSMCs activities in human aortic VSMCs stimulated with platelet-derived growth factor-BB (PDGF-BB). Using rat embryonic aorta-derived A7r5 VSMCs which do not express TM, the role of the chondroitin sulfate (CS) moiety of TM in VSMCs was delineated with cells expressing wild-type TM and the CS-devoid TM mutant. Results: Expression of TM enhanced cell migration and adhesion/spreading onto type I collagen, but had no effect on cell proliferation. Knocking down TM with short hairpin RNA reduced PDGF-stimulated adhesion and migration of human aortic VSMCs. In A7r5 cells, TM-mediated cell adhesion was eradicated by pretreatment with chondroitinase ABC which degrades CS moiety. Furthermore, the TM mutant (TMS490, 492A)devoidofCS moiety failed to increase cell adhesion, spreading or migration. Wild-type TM, but not TMS490, 492A,increased focal adhesion kinase (FAK) activation during cell adhesion, and TM-enhanced cell migration was abolished by a function-blocking anti-integrin β1 antibody.
    [Show full text]
  • Proteomics Provides Insights Into the Inhibition of Chinese Hamster V79
    www.nature.com/scientificreports OPEN Proteomics provides insights into the inhibition of Chinese hamster V79 cell proliferation in the deep underground environment Jifeng Liu1,2, Tengfei Ma1,2, Mingzhong Gao3, Yilin Liu4, Jun Liu1, Shichao Wang2, Yike Xie2, Ling Wang2, Juan Cheng2, Shixi Liu1*, Jian Zou1,2*, Jiang Wu2, Weimin Li2 & Heping Xie2,3,5 As resources in the shallow depths of the earth exhausted, people will spend extended periods of time in the deep underground space. However, little is known about the deep underground environment afecting the health of organisms. Hence, we established both deep underground laboratory (DUGL) and above ground laboratory (AGL) to investigate the efect of environmental factors on organisms. Six environmental parameters were monitored in the DUGL and AGL. Growth curves were recorded and tandem mass tag (TMT) proteomics analysis were performed to explore the proliferative ability and diferentially abundant proteins (DAPs) in V79 cells (a cell line widely used in biological study in DUGLs) cultured in the DUGL and AGL. Parallel Reaction Monitoring was conducted to verify the TMT results. γ ray dose rate showed the most detectable diference between the two laboratories, whereby γ ray dose rate was signifcantly lower in the DUGL compared to the AGL. V79 cell proliferation was slower in the DUGL. Quantitative proteomics detected 980 DAPs (absolute fold change ≥ 1.2, p < 0.05) between V79 cells cultured in the DUGL and AGL. Of these, 576 proteins were up-regulated and 404 proteins were down-regulated in V79 cells cultured in the DUGL. KEGG pathway analysis revealed that seven pathways (e.g.
    [Show full text]
  • Blood-Based Molecular Biomarker Signatures in Alzheimer's
    bioRxiv preprint doi: https://doi.org/10.1101/481879; this version posted December 31, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Article Blood-based molecular biomarker signatures in Alzheimer’s disease: insights from systems biomedicine perspective Tania Islam 1,#, Md. Rezanur Rahman 2,#,*, Md. Shahjaman3, Toyfiquz Zaman2, Md. Rezaul Karim2, Julian M.W. Quinn4, R.M. Damian Holsinger5,6, and Mohammad Ali Moni 6,* 1Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh; [email protected](T.I.). 2 Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Sirajgonj, Bangladesh; [email protected](M.R.R.). 3 Department of Statistics, Begum Rokeya University, Rangpur, Bangladesh; [email protected] (M.S.). 4 Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia;[email protected](J.W.W.Q.). 5 Laboratory of Molecular Neuroscience and Dementia, Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia; [email protected] (R.M.D.H.). 6 Discipline of Biomedical Science, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia; [email protected] (M.A.M.). #These two authors have made an equal contribution and hold joint first authorship for this work. * Correspondence: [email protected] (M.R.R.) or [email protected] (M.A.M.). Abstract: Background and objectives: Alzheimer’s disease (AD) is the progressive neurodegenerative disease characterized by dementia, but no peripheral biomarkers available yet that can detect the AD.
    [Show full text]
  • Characterization of Genetic Aberrations in a Single Case of Metastatic Thymic Adenocarcinoma Yeonghun Lee1, Sehhoon Park2, Se-Hoon Lee2,3* and Hyunju Lee1*
    Lee et al. BMC Cancer (2017) 17:330 DOI 10.1186/s12885-017-3282-9 RESEARCH ARTICLE Open Access Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma Yeonghun Lee1, Sehhoon Park2, Se-Hoon Lee2,3* and Hyunju Lee1* Abstract Background: Thymic adenocarcinoma is an extremely rare subtype of thymic epithelial tumors. Due to its rarity, there is currently no sequencing approach for thymic adenocarcinoma. Methods: We performed whole exome and transcriptome sequencing on a case of thymic adenocarcinoma and performed subsequent validation using Sanger sequencing. Results: The case of thymic adenocarcinoma showed aggressive behaviors with systemic bone metastases. We identified a high incidence of genetic aberrations, which included somatic mutations in RNASEL, PEG10, TNFSF15, TP53, TGFB2, and FAT1. Copy number analysis revealed a complex chromosomal rearrangement of chromosome 8, which resulted in gene fusion between MCM4 and SNTB1 and dramatic amplification of MYC and NDRG1. Focal deletion was detected at human leukocyte antigen (HLA) class II alleles, which was previously observed in thymic epithelial tumors. We further investigated fusion transcripts using RNA-seq data and found an intergenic splicing event between the CTBS and GNG5 transcript. Finally, enrichment analysis using all the variants represented the immune system dysfunction in thymic adenocarcinoma. Conclusion: Thymic adenocarcinoma shows highly malignant characteristics with alterations in several cancer- related genes. Keywords: Thymic adenocarcinoma, Thymic epithelial tumors, Whole exome sequencing, Somatic mutations, Somatic copy number alterations Background With their distinct entities, thymic adenocarcinomas Thymic adenocarcinoma is an extremely rare subtype of have shown higher malignancy than other thymic epi- thymic carcinoma. Thirty-five cases have been reported thelial tumors (TETs).
    [Show full text]